New EVF Guidelines publication entitled Management of CVD of lower limbs – Part II reports Sulodexide scientific evidences in the dedicated chapter to Prevention of Post-Thrombotic Syndrome, definin...

Innovation Pharmaceuticals announces License Agreement with Alfasigma S.p.A. for the development and commercialization of Brilacidin in Ulcerative Proctitis/Ulcerative Proctosigmoiditis....

Alfasigma USA has acquired the brand ZELNORM (tegaserod), a treatment for IBS-C, from Sloan Pharma, with the aim to relaunch the brand in the United States....